Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

被引：24

作者：

Wierda, William G. ^{[1
]}

Lewis, David John ^{[2
]}

Ghia, Paolo ^{[3
,4
]}

Shah, Nirav N. ^{[5
]}

Coombs, Catherine C. ^{[6
]}

Cheah, Chan Y. ^{[7
,8
]}

Lamanna, Nicole ^{[9
]}

Rhodes, Joanna M. ^{[10
]}

Hoffmann, Marc ^{[11
]}

Ma, Shuo ^{[12
]}

Eyre, Toby A. ^{[13
]}

Munir, Talha ^{[14
]}

Patel, Manish R. ^{[15
]}

Alencar, Alvaro J. ^{[16
]}

Tam, Constantine S. ^{[17
,18
]}

Seymour, John F. ^{[19
]}

Jurczak, Wojciech ^{[20
]}

Lech-Maranda, Ewa ^{[21
]}

Roeker, Lindsey E. ^{[22
]}

Thompson, Philip A. ^{[1
]}

Abada, Paolo B. ^{[23
]}

Wang, Chunxiao ^{[24
]}

Nair, Binoj ^{[23
]}

Liu, Hui ^{[23
]}

Tsai, Donald E. ^{[23
]}

Mato, Anthony R. ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Plymouth Hosp NHS Trust, Derriford Hosp, Plymouth, Devon, England

[3] Univ Vita Salute San Raffaele, Milan, Italy

[4] IRCCS Osped San Raffaele, Milan, Italy

[5] Med Coll Wisconsin, Brookfield, WI USA

[6] Univ N Carolina, Chapel Hill, NC 27515 USA

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York Presbyterian, New York, NY USA

[10] Northwell Hlth Canc Inst, New Hyde Pk, NY USA

[11] Univ Kansas, Ctr Canc, Kansas City, KS USA

[12] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA

[13] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[14] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[15] Sarah Cannon Res Inst, Sarasota, FL USA

[16] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

[17] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[18] Univ Melbourne, Melbourne, Vic, Australia

[19] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[20] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[21] Inst Hematol & Transfus Med, Warsaw, Poland

[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[23] Loxo Lilly, Indianapolis, IN USA

[24] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157058

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Discovery of GDC-0853: A highly potent, selective, and non-covalent Btk inhibitor
Young, Wendy
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[32] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo B.
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BLOOD, 2022, 140 : 2316 - 2320
[33] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
Cohen, Jonathon B.
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fahkri, Bita
Jurczak, Wojciech
Tan, Xuan N.
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian
Lewis, David J.
Le Gouill, Stephen
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S378 - S379
[34] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN Study
Brown, Jennifer
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel C.
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Mato, Anthony
Gandhi, Varsha
Wierda, William
LEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26
[35] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Gerson, James N.
Flinn, Ian W.
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna M.
Patel, Krish
Woyach, Jennifer A.
Lamanna, Nicole
Wang, Yucai
Tam, Constantine S.
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew D.
Jain, Preetesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo B.
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BLOOD, 2022, 140 : 9368 - 9372
[36] Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Y.
Lewis, David
Hoffman, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Shuo, M. A.
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna
Mckinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro
Patel, Manish R.
Seymour, John F.
Woyach, Jennifer
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo
Ho, Caleb
Marella, Narasimha
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Ghia, Paolo
Al-Sawaf, Othman
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 120 - 121
[37] Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Izutsu, Koji
Ma, Shuo
Flinn, Ian
Alencar, Alvaro J.
Lewis, David
Patel, Krish
Maddocks, Kami
Wang, Yucai
Munir, Talha
Zelenetz, Andrew D.
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S459 - S459
[38] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
Lewis, David John
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutzu, Koji
Gerson, James N.
Flinn, Ian
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna
Patel, Krish
Woyach, Jennifer
Lamanna, Nicole
Wang, Yucai
Tam, Constantine
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew
Jain, Preteesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 108 - 109
[39] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN
Munir, Talha
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 110 - 111
[40] Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
Gomez, Eliana B.
Isabel, Lippincott
Rosendahal, Mary S.
Rothenberg, Stephen M.
Andrews, Steven W.
Brandhuber, Barb J.
BLOOD, 2019, 134

← 1 2 3 4 5 →